Previous close | 1.0800 |
Open | 1.0800 |
Bid | 0.0100 |
Ask | 2.1500 |
Strike | 240.00 |
Expiry date | 2025-01-17 |
Day's range | 1.0800 - 1.0800 |
Contract range | N/A |
Volume | |
Open interest | 199 |
Novo Nordisk's (NVO) Ozempic and Wegouvy and Eli Lilly's (LLY) Zepbound are the leading names in the latest GLP-1 weight loss drug cycle, a trend that has seen a variety of use cases sprout up since these brand names' inceptions late last year. Yahoo Finance Health Reporter Anjalee Khemlani explains the new use cases being found for this class of drugs, including infertility treatments and even benefits for Alzheimer's patients. For more expert insight and the latest market action, click here to watch this full episode. This post was written by Luke Carberry Mogan.
Eli Lilly and Company (LLY) shares are up in 2024 to the tune of 28% so far. Looking under the surface, it’s clear to see why this biopharmaceuticals stock is so powerful.
J&J (JNJ) posts mixed first-quarter 2024 results. Lilly's (LLY) tirzepatide meets key goals in late-stage studies for obstructive sleep apnea.